Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H23N3O2 |
| Molecular Weight | 337.4155 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(OCCN2CCOCC2)=NN1C3=CC4=C(C=CC=C4)C=C3
InChI
InChIKey=DGPGXHRHNRYVDH-UHFFFAOYSA-N
InChI=1S/C20H23N3O2/c1-16-14-20(25-13-10-22-8-11-24-12-9-22)21-23(16)19-7-6-17-4-2-3-5-18(17)15-19/h2-7,14-15H,8-13H2,1H3
| Molecular Formula | C20H23N3O2 |
| Molecular Weight | 337.4155 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:40:20 UTC 2023
by
admin
on
Sat Dec 16 10:40:20 UTC 2023
|
| Record UNII |
ZW18DSD1H4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
S1RA
Created by
admin on Sat Dec 16 10:40:20 UTC 2023 , Edited by admin on Sat Dec 16 10:40:20 UTC 2023
|
PRIMARY | S1RA, E-52862, or 4-(2-((5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yl)oxy)ethyl)morpholine is a selective sigma-1 receptor antagonist, with a reported binding affinity of Ki = 17.0 +/- 7.0 nM, selective over the sigma-2 receptor and against a panel of other 170 receptors, enzymes, transporters and ion channels.(1)(2) In preclinical studies, S1RA has demonstrated efficacy in relieving neuropathic pain and pain in other sensitizing conditions, associated with an improvement of the emotional negative state.S1RA is being developed by Esteve for the treatment of neuropathic pain and the potentiation of opioid analgesia and has successfully completed Phase I clinical trials showing good safety and tolerability, and a pharmacokinetic profile compatible with once a day oral administration. Phase II clinical trials are currently underway, making S1RA the first selective sigma-1 receptor antagonist evaluated in humans for these conditions. | ||
|
878141-96-9
Created by
admin on Sat Dec 16 10:40:20 UTC 2023 , Edited by admin on Sat Dec 16 10:40:20 UTC 2023
|
PRIMARY | |||
|
100000175800
Created by
admin on Sat Dec 16 10:40:20 UTC 2023 , Edited by admin on Sat Dec 16 10:40:20 UTC 2023
|
PRIMARY | |||
|
ZW18DSD1H4
Created by
admin on Sat Dec 16 10:40:20 UTC 2023 , Edited by admin on Sat Dec 16 10:40:20 UTC 2023
|
PRIMARY | |||
|
DTXSID90102252
Created by
admin on Sat Dec 16 10:40:20 UTC 2023 , Edited by admin on Sat Dec 16 10:40:20 UTC 2023
|
PRIMARY | |||
|
44247568
Created by
admin on Sat Dec 16 10:40:20 UTC 2023 , Edited by admin on Sat Dec 16 10:40:20 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Ki
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Active Indications (Highest Phase): Phase II for Diabetic neuropathies, Neuropathic pain, Postherpetic neuralgia, Postoperative pain
No Inactive Indications
|
